RAD-140 (Testolone)

RAD-140 selectively binds the androgen receptor in muscle and bone tissue with high affinity and potency. It activates anabolic signaling cascades (mTOR, Akt) that drive protein synthesis and muscle hypertrophy. Crucially, RAD-140 acts as an antagonist in the prostate, meaning it does not stimulate prostate growth like exogenous testosterone would. In preclinical studies, RAD-140 also demonstrated neuroprotective properties, protecting hippocampal neurons against kainate-induced excitotoxicity, suggesting potential cognitive benefits.

RAD-140 has excellent oral bioavailability. Peak plasma concentration is reached within 2-4 hours. The long half-life of approximately 60 hours means steady-state levels are achieved after about one week of daily dosing. It does not aromatize to estrogen and is not a substrate for 5-alpha reductase (so it does not convert to DHT). Metabolism is primarily hepatic, though it is non-methylated and considered less hepatotoxic than methylated oral steroids or YK-11.

• ✓Rapid lean muscle mass gains (5-10 lbs in 8-12 weeks, depending on training and diet)
• ✓Significant strength increases, often noticeable within 2 weeks
• ✓Enhanced muscle hardness and density without water retention
• ✓Neuroprotective effects (preclinical data)
• ✓Does not aromatize; no estrogenic side effects
• ✓Does not convert to DHT; lower risk of hair loss compared to androgenic compounds
• ✓Improved recovery between training sessions
• ✓Enhanced vascularity and muscle pumps

• ⚠Testosterone suppression (dose-dependent; moderate at 10 mg, significant at 20 mg)
• ⚠HDL cholesterol suppression (typically 20-30% reduction)
• ⚠Mild liver enzyme elevation in some users (generally less than methylated compounds)
• ⚠Potential hair shedding in those highly predisposed (less common than with DHT-derived compounds)
• ⚠Lethargy and fatigue in the later weeks of a cycle as suppression deepens
• ⚠Potential aggression or irritability
• ⚠Temporary reduction in natural libido during suppressed state

Contraindications

• 🚫Pre-existing liver disease
• 🚫Hormone-sensitive cancers
• 🚫Women who are pregnant or breastfeeding
• 🚫Males under 21 years of age
• 🚫Individuals with severely compromised lipid profiles or cardiovascular disease
• 🚫Those on medications that are CYP3A4 substrates (potential interaction)

**PCT is required.** RAD-140 at any meaningful dose will suppress testosterone. **Standard PCT (8-week cycle at 10-15 mg):** - Nolvadex (Tamoxifen) 20 mg/day for 4 weeks **Aggressive PCT (12-week cycle or doses of 20 mg):** - Nolvadex 40/40/20/20 mg over 4 weeks, OR - Clomid 50/25/25/25 mg over 4 weeks Due to the long half-life (~60 hours), wait 3-4 days after last dose before beginning PCT to allow RAD-140 levels to drop. Recheck bloodwork 4-6 weeks after PCT completion.

• 1.The long half-life means you only need to dose once daily; consistency matters more than timing
• 2.RAD-140 tastes terrible in liquid form; chase it with juice or use capsules
• 3.Expect your SHBG to crater; this is normal and recovers post-cycle
• 4.If you experience significant lethargy in weeks 6-8, it is likely suppression, not the compound being "toxic"
• 5.RAD-140 is one of the best SARMs for a first cycle alongside Ostarine
• 6.Keep protein intake high (1g+ per lb bodyweight) to maximize the anabolic window
• 7.Consider adding Cardarine (GW-501516) for endurance and fat loss synergy
• 8.Do not stack with other suppressive SARMs on your first cycle

1. [1]Miller CP, et al. (2011). Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett.
2. [2]Jayaraman A, et al. (2014). Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology.